Explore macrophage inflammatory protein-1 alpha, CCR1, CCR5, and the recruitment of myeloid cells and lymphocytes.
Search results
273 resources20 duplicate listings grouped
What’s searchable?CCL3 encodes MIP-1 alpha, a chemokine involved in attracting and activating immune cells. It is related to CCL4, or MIP-1 beta, but the two genes and proteins are distinct.
A compound made in the body that participates in the citric acid cycle and amino-acid metabolism.
Not a routine vitamin D status test. Ask your clinician to read this result with calcium, phosphorus, kidney function, and PTH.
Interpret relative to lipids when appropriate; assay-specific.
Sample handling and test methods can change a cytokine result. Compare it with the exact range from your lab and ask why the test was ordered.
Age, sex, nutrition, liver disease, diabetes, and assay matter.
Explore macrophage inflammatory protein-1 beta, CCR5, T cells, natural killer cells, and monocytes. Understand the connection CCL4, also called MIP-1 beta, is a chemical signal that attracts immune cells, particularly through CCR5. It is r…
Explore the allergy response and the immune signals discussed in Dr. Purser’s alpha-gal report.
Membranous nephropathy affects the kidney’s filtering units.
CCL4 encodes MIP-1 beta, a chemokine involved in attracting immune cells. It participates in a recruitment network that includes CCL2, CXCL8 and related chemokines.
Explore tumor necrosis factor-alpha, TNFR1, TNFR2, rs1800629, inflammatory signaling, and treatment comparisons in Purser Wellness teaching.
About search coverage
Search looks for your words in titles, descriptions, available articles, learning guides, and video captions when available. The closest matches appear first. Duplicate posts are grouped, with links to other places you can read or watch them. Books, chapters, and reports have topic guides here; the original files and full book text are not available in this encyclopedia. Subscriber posts include a title and public summary; open Substack to read the full post.
